bms 512148

Dapagliflozin (BMS-512148) is a selective sodium-glucose co-transporter subtype 2 (SGLT2) inhibitor with antihyperglycemic activity.

Dapagliflozin ((2S)-1,2-propanediol, hydrate) (BMS-512148 (2S)-1,2-propanediol, hydrate) is a selective, orally active inhibitor of the renal sodium-glucose co-transporter type 2 (SGLT2), in development for treating type 2 diabetes mellitus (T2DM). It inhibits SGLT2, responsible for at least 90% of glucose reabsorption in the kidney.

Dapagliflozin-D5 is a deuterated form of Dapagliflozin (T2389), a competitive SGLT2 inhibitor.

Dapagliflozin (Standard) is a reference standard for research and analysis in studies involving Dapagliflozin. Dapagliflozin (BMS-512148) is a glucose co-transporter protein 2 (SGLT2) inhibitor that competitively binds to its target. Dapagliflozin is used in the treatment of type 2 diabetes mellitus and decreases glucose reabsorption in the kidneys and increases urinary excretion of glucose, which results in lowering plasma glucose levels.